Navigation Links
Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects

ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 /PRNewswire/ -- Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics' NextGENe software for next-generation sequencing projects performed at Ambry.


Anja Kammesheidt PhD, Ambry's CSO said, "Our team at Ambry has been providing genomics solutions on Illumina's® Genome Analyzer platform for 2 years now. In light of diversifying applications, increasing project sizes, and new genomes to be explored, having a proven and innovative partner for bioinformatics is key. While some of our clients are interested in performing their own analyses, others are asking for extended support. We have been impressed with SoftGenetics' software tools, as well as their approach to take care of the clients' needs which is very much in line with Ambry's philosophy. We are looking forward to working together to provide tailored services to our clients."

Jonathan Liu PhD, SoftGenetics VP Research and Development echoed Dr. Kammesheidt's thoughts and added that, "the SoftGenetics/Ambry partnership provides a new strategic alliance that will not only provide a single streamlined source for next-generation sequencing researchers, but will also provide SoftGenetics with a deepened vision of future researcher requirements, allowing NextGENe to remain at the forefront of next-generation sequencing software."

"This highly unique alliance," continued John Fosnacht, SoftGenetics VP Sales and Marketing, "provides researchers wishing to utilize the power of next-generation sequencing a distinctive value proposition by combining the technical quality of Ambry Genetics sequencing with the unique analysis capabilities of NextGENe without the heavy investment typically required in next-generation sequencing instrumentation and bioinformatics. We all believe this is a true win-win situation for everyone."

"Next-generation sequencing services are more valuable to any scientific researcher if you can offer a full menu for bioinformatics support," said Ardy Arianpour, Director of Business Development, Genomic Services at Ambry Genetics. "Ambry Genetics has now become the genomics community's one-stop service shop for next-generation sequencing services. We can handle large projects and we can offer the most robust data analysis through the exclusive alliance with SoftGenetics."

Ambry Genetics has been providing next generation sequencing services to pharmaceutical, biotech and academic clients for a wide range of applications including targeted resequencing through custom or exome sequence capture, transcriptome, ChIP and de novo sequencing. Ambry Genetics is focused on delivering the highest quality results with the most sensible workflows while maintaining cost effective contracts for the genomics community.

About Ambry Genetics

Ambry Genetics is both a clinical, CAP-accredited and CLIA-certified commercial laboratory as well as a genomics services laboratory headquartered in Aliso Viejo, California. Since the company's inception in 2000, it has become a leader in providing genetic services focused on clinical diagnostics and genomic services. Ambry has built a solid reputation for unparalleled service, and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and advancements in disease research. To learn more about testing and services available through Ambry, visit

About SoftGenetics

SoftGenetics, LLC, located in State College Pennsylvania specializes in the development of genetic analysis tools for both research and diagnostic applications. Hallmarks of SoftGenetics software tools are advanced technologies, providing exceptional accuracy, and sensitivity in an easy-to-use Windows® user interface.

Its NextGENe software provides biologists with an easy-to-use software analysis tool which improves Next Generation Sequencing accuracy in a complete, freestanding Windows® based program. NextGENe virtually eliminates bioinformatics requirements, utilizes low cost hardware, and is compatible with all major NGS systems

To learn more or to request a 30-day trial of the software, please visit:

SOURCE Ambry Genetics; SoftGenetics

SOURCE Ambry Genetics; SoftGenetics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Genetics Determine Optimal Drug Dose of Common Anticoagulant
4. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
5. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
6. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
7. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
8. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
9. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
10. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
11. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
Post Your Comments:
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):